Cargando…
Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report
BACKGROUND: Pembrolizumab is an immune-checkpoints inhibitor that enhances the immune response against cancer cells and therefore is useful for the treatment of several carcinomas. However, pembrolizumab sometimes perturbs the immune system resulting in various autoimmune neurological complications....
Autores principales: | Kamo, Hikaru, Hatano, Taku, Kanai, Kazuaki, Aoki, Nozomi, Kamiyama, Daiki, Yokoyama, Kazumasa, Takanashi, Masashi, Yamashita, Yuri, Shimo, Yasushi, Hattori, Nobutaka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681482/ https://www.ncbi.nlm.nih.gov/pubmed/31382909 http://dx.doi.org/10.1186/s12883-019-1416-1 |
Ejemplares similares
-
Myalgia caused by chronic myositis associated with plasmacytosis: a case report
por: Hatano, Taku, et al.
Publicado: (2018) -
Pembrolizumab‐induced myasthenia gravis with myositis in a patient with lung cancer
por: Hibino, Makoto, et al.
Publicado: (2018) -
Emergence of Myasthenia Gravis with Myositis in a Patient Treated with Pembrolizumab for Thymic Cancer
por: Huh, So-Young, et al.
Publicado: (2018) -
Pembrolizumab-Induced Ocular Myasthenic Crisis
por: Lorenzo, Christian J, et al.
Publicado: (2020) -
Pembrolizumab‐induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer
por: Todo, Maki, et al.
Publicado: (2019)